UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B

Hepatology (Baltimore, Md.), 2021-01, Vol.73 (1), p.53-67

2021

Volltextzugriff (PDF)

Cell-Free Hepatitis B Virus Capsid Assembly Dependent on the Core Protein C-Terminal Domain and Regulated by Phosphorylation

Journal of virology, 2016-06, Vol.90 (12), p.5830-5844

2016

Volltextzugriff (PDF)

Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B

Journal of medicinal chemistry, 2020-09, Vol.63 (18), p.10188-10203

2020

Volltextzugriff (PDF)

Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism

Journal of hepatology, 2018-05, Vol.68 (5), p.922-931

2018

Volltextzugriff (PDF)

Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell Lines

Journal of virology, 2021-09, Vol.95 (19), p.e0029921-e0029921

2021

Volltextzugriff (PDF)

Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells

Journal of hepatology, 2018-05, Vol.68 (5), p.912-921

2018

Volltextzugriff (PDF)

Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo

Molecular therapy, 2022-09, Vol.30 (9), p.2909-2922

2022

Volltextzugriff (PDF)

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

Antimicrobial agents and chemotherapy, 2023-01, Vol.67 (1), p.e0134822

2023

Volltextzugriff (PDF)

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy

Gastroenterology (New York, N.Y. 1943), 2004-06, Vol.126 (7), p.1750-1758

2004

Volltextzugriff (PDF)

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

Antimicrobial Agents and Chemotherapy, 2006-07, Vol.50 (7), p.2471-2477

2006

Volltextzugriff (PDF)

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents

Antiviral therapy, 2007-01, Vol.12 (3), p.355-362

2007

Volltextzugriff (PDF)

Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment

Journal of virological methods, 2017-11, Vol.249, p.189-193

2017

Volltextzugriff (PDF)

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

PloS one, 2022-12, Vol.17 (12), p.e0271145-e0271145

2022

Volltextzugriff (PDF)

The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

Journal of Virology, 2003-11, Vol.77 (21), p.11833-11841

2003

Volltextzugriff (PDF)

New therapeutic targets and drugs for the treatment of chronic hepatitis B

Seminars in liver disease, 2013-05, Vol.33 (2), p.130-137

2013

Volltextzugriff (PDF)

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals

Proceedings of the National Academy of Sciences - PNAS, 2011-06, Vol.108 (25), p.10290-10295

2011

Volltextzugriff (PDF)

Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873

ACS medicinal chemistry letters, 2024-04, Vol.15 (4), p.546-554

2024

Volltextzugriff (PDF)

Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome

Antiviral research, 2013-07, Vol.99 (1), p.34-48

Delaney, William E.

2013

Volltextzugriff (PDF)

Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.647-653

2014

Volltextzugriff (PDF)

Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease

Bioorganic & medicinal chemistry letters, 2012-04, Vol.22 (7), p.2629-2634

2012

Volltextzugriff (PDF)

Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity

Bioorganic & medicinal chemistry letters, 2012-02, Vol.22 (3), p.1394-1396

2012

Volltextzugriff (PDF)

Novel Mutations in a Tissue Culture-Adapted Hepatitis C Virus Strain Improve Infectious-Virus Stability and Markedly Enhance Infection Kinetics

Journal of Virology, 2011-04, Vol.85 (8), p.3978-3985

2011

Volltextzugriff (PDF)

A Small-Molecule Inhibitor of Hepatitis C Virus Infectivity

Antimicrobial Agents and Chemotherapy, 2014-01, Vol.58 (1), p.386-396

2014

Volltextzugriff (PDF)

Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro

Antimicrobial Agents and Chemotherapy, 2002-09, Vol.46 (9), p.3057-3060

2002

Volltextzugriff (PDF)

Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures

PloS one, 2013-06, Vol.8 (6), p.e65273

2013

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)
Japanisch
(15)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B

Cell-Free Hepatitis B Virus Capsid Assembly Dependent on the Core Protein C-Terminal Domain and Regulated by Phosphorylation

Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B

Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism

Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell Lines

Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells

Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents

Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

New therapeutic targets and drugs for the treatment of chronic hepatitis B

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals

Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873

Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome

Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451

Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease

Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity

Novel Mutations in a Tissue Culture-Adapted Hepatitis C Virus Strain Improve Infectious-Virus Stability and Markedly Enhance Infection Kinetics

A Small-Molecule Inhibitor of Hepatitis C Virus Infectivity

Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro

Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures

Suchergebnisse filtern